Article and Video CATEGORIES
As part of our program on lung cancer highlights, Dr. Joel Neal covered the LUX-Lung 3 trial, a global study that randomized patients with advanced NSCLC and an EGFR mutation to either afatinib, an "irreversible pan-HER inhibitor" that could potentially be an advance over the current EGFR inhibitors we have available now, or standard chemotherapy with cisplatin/Alimta (pemetrexed). It provided some interesting results, though the question is whether the performance of afatinib exceeded what we might expect from Tarceva (erlotinib) or Iressa (gefitinib), except in terms of side effects, which were more severe and more common with afatinib. Still, it was a positive trial that I expect will lead to an FDA approval and the commercial availability of afatinib for this clinical population.
Here's Dr. Neal's coverage of the trial, in both video and audio podcast form, as well as the associated transcript and figures for the podcast.
Dr. Neal ASCO 2012 LC Highlights LUX-Lung 3 Audio Podcast
Dr. Neal ASCO 2012 LC Highlights LUX-Lung 3 Figs
Dr. Neal ASCO LC Highlights 2012 LUX-Lung 3 Transcript
In short order we'll have Dr. Neal's summary of the interesting trial of the MEK inhibitor selumetinib for KRAS mutation-positive patients available, too; in the meantime, what do you think of these results? Would you be inclined to favor afatinib now if you had an EGFR mutation, or would you favor Iressa or Tarceva instead? How much does your answer depend on the survival results for the afatinib?
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.
Glad to help. FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/
Hope to see...